Predictive Modeling of Drug Response in Non-Hodgkin’s Lymphoma
暂无分享,去创建一个
Sanjiv S. Gambhir | Vittorio Cristini | Hermann B. Frieboes | Shannon M. Mumenthaler | Parag Mallick | Bryan R. Smith | Armin Day | Eman Simbawa | Ken Ito | H. Frieboes | V. Cristini | S. Gambhir | P. Mallick | B. Smith | S. Mumenthaler | Zhihui Wang | Ken Ito | M. Kotsuma | Armin Day | Benjamin Cahill | Colin Flinders | Eman Simbawa | A. S. Al-Fhaid | S. R. Mahmoud | Zhihui Wang | Masakatsu Kotsuma | Benjamin Cahill | Colin Flinders | A. S. AL-Fhaid
[1] Mauro Ferrari,et al. Transport properties of pancreatic cancer describe gemcitabine delivery and response. , 2014, The Journal of clinical investigation.
[2] V. Seshan,et al. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] P K Maini,et al. A mathematical model of Doxorubicin treatment efficacy for non-Hodgkin’s lymphoma: Investigation of the current protocol through theoretical modelling results , 2005, Bulletin of mathematical biology.
[4] Nikolaos K. Uzunoglu,et al. A spatiotemporal, patient individualized simulation model of solid tumor response to chemotherapy in vivo: the paradigm of glioblastoma multiforme treated by temozolomide , 2006, IEEE Transactions on Biomedical Engineering.
[5] I. Tannock,et al. Drug resistance and the solid tumor microenvironment. , 2007, Journal of the National Cancer Institute.
[6] I. Glauche,et al. Pathogenesis, treatment effects, and resistance dynamics in chronic myeloid leukemia - insights from mathematical model analyses , 2007, Journal of Molecular Medicine.
[7] M. Perry. The Chemotherapy Source Book , 1992, Annals of Internal Medicine.
[8] G. Melillo,et al. Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia , 2012, Nature Reviews Clinical Oncology.
[9] M. Meyer-Hermann,et al. Are T cells at the origin of B cell lymphomas? , 2007, Journal of theoretical biology.
[10] P. Comoglio,et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. , 2003, Cancer cell.
[11] M. Chaplain,et al. A mathematical model of breast cancer development, local treatment and recurrence. , 2007, Journal of theoretical biology.
[12] Jana L. Gevertz,et al. Computational Modeling of Tumor Response to Vascular-Targeting Therapies—Part I: Validation , 2011, Comput. Math. Methods Medicine.
[13] Società Italiana di Emaferesi. Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis , 2001 .
[14] Zhihui Wang,et al. Cross-scale, cross-pathway evaluation using an agent-based non-small cell lung cancer model , 2009, Bioinform..
[15] R. Crownover. Hematology/Oncology Clinics of North America: Preface , 1999 .
[16] C. Dang,et al. Biology and treatment of Burkitt's lymphoma , 2007, Current opinion in hematology.
[17] Min Wu,et al. The effect of interstitial pressure on tumor growth: coupling with the blood and lymphatic vascular systems. , 2013, Journal of theoretical biology.
[18] M. Ogura,et al. Phase I study of BCX1777 (forodesine) in patients with relapsed or refractory peripheral T/natural killer‐cell malignancies , 2012, Cancer science.
[19] I. Tannock,et al. Drug penetration in solid tumours , 2006, Nature Reviews Cancer.
[20] ffalourd. Mathematics and algorithms , 2017 .
[21] Joon-Kee Yoon,et al. Unexpected dissemination patterns in lymphoma progression revealed by serial imaging within a murine lymph node. , 2012, Cancer research.
[22] Zhihui Wang,et al. Development of a sampling-based global sensitivity analysis workflow for multiscale computational cancer models. , 2014, IET systems biology.
[23] Mauro Ferrari,et al. Prediction of drug response in breast cancer using integrative experimental/computational modeling. , 2009, Cancer research.
[24] M. Westphal,et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. , 2001, Cancer research.
[25] S. Goldman,et al. Hematology/Oncology Clinics of North America , 2020, Hematology/Oncology Clinics of North America.
[26] M. Bodnar,et al. About a generalized model of lymphoma , 2012 .
[27] Jason M. Graham,et al. A spatial model of tumor-host interaction: application of chemotherapy. , 2008, Mathematical biosciences and engineering : MBE.
[28] O. O’Connor,et al. New drugs for the treatment of lymphoma. , 2008, Hematology/oncology clinics of North America.
[29] T. Grogan,et al. Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining. , 1989, Journal of the National Cancer Institute.
[30] Vittorio Cristini,et al. Mechanistic modeling identifies drug-uptake history as predictor of tumor drug resistance and nano-carrier-mediated response. , 2013, ACS nano.
[31] Sharon E Ungersma,et al. Vessel imaging with viable tumor analysis for quantification of tumor angiogenesis , 2010, Magnetic resonance in medicine.
[32] K. Savage,et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] Vittorio Cristini,et al. Mechanistic patient-specific predictive correlation of tumor drug response with microenvironment and perfusion measurements , 2013, Proceedings of the National Academy of Sciences.
[34] Ken Ito,et al. An Integrated Computational/Experimental Model of Lymphoma Growth , 2013, PLoS Comput. Biol..
[35] B Ribba,et al. A multiscale mathematical model of avascular tumor growth to investigate the therapeutic benefit of anti-invasive agents. , 2006, Journal of theoretical biology.
[36] Vittorio Cristini,et al. Three-dimensional multispecies nonlinear tumor growth-II: Tumor invasion and angiogenesis. , 2010, Journal of theoretical biology.
[37] P. Maini,et al. MODELLING THE RESPONSE OF VASCULAR TUMOURS TO CHEMOTHERAPY: A MULTISCALE APPROACH , 2006 .
[38] H. Frieboes,et al. An integrated computational/experimental model of tumor invasion. , 2006, Cancer research.
[39] Soyoung Lee,et al. A Senescence Program Controlled by p53 and p16INK4a Contributes to the Outcome of Cancer Therapy , 2002, Cell.
[40] Karen M Page,et al. Mathematical models of the fate of lymphoma B cells after antigen receptor ligation with specific antibodies. , 2006, Journal of theoretical biology.
[41] Vittorio Cristini,et al. Predictions of tumour morphological stability and evaluation against experimental observations , 2011, Journal of The Royal Society Interface.
[42] Zhihui Wang,et al. Cross-scale sensitivity analysis of a non-small cell lung cancer model: Linking molecular signaling properties to cellular behavior , 2007, Biosyst..
[43] J. Teruya-Feldstein,et al. The Schedule-Dependent Effects of the Novel Antifolate Pralatrexate and Gemcitabine Are Superior to Methotrexate and Cytarabine in Models of Human Non-Hodgkin's Lymphoma , 2006, Clinical Cancer Research.
[44] Mauro Ferrari,et al. Predicting drug pharmacokinetics and effect in vascularized tumors using computer simulation , 2008, Journal of mathematical biology.
[45] Society of magnetic resonance in medicine , 1990 .
[46] Zhuang Liu,et al. High-resolution, serial intravital microscopic imaging of nanoparticle delivery and targeting in a small animal tumor model. , 2013, Nano today.
[47] Dirk Hasenclever,et al. Modelling Lymphoma Therapy and Outcome , 2014, Bulletin of mathematical biology.
[48] Mary E. Edgerton,et al. A Novel, Patient-Specific Mathematical Pathology Approach for Assessment of Surgical Volume: Application to Ductal Carcinoma in situ of The Breast , 2011, Analytical cellular pathology.
[49] J. Kuruvilla,et al. Relapsed and refractory aggressive NHL: time for a change. , 2013, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.
[50] Vittorio Cristini,et al. Impact of Diffusion Barriers to Small Cytotoxic Molecules on the Efficacy of Immunotherapy in Breast Cancer , 2013, PloS one.
[51] S. Lowe,et al. Tumor suppression by Ink4a-Arf: progress and puzzles. , 2003, Current opinion in genetics & development.
[52] Carlo Giussani,et al. Combinatorial Administration of Molecules That Simultaneously Inhibit Angiogenesis and Invasion Leads to Increased Therapeutic Efficacy in Mouse Models of Malignant Glioma , 2004, Clinical Cancer Research.
[53] Lothar Lilge,et al. The Distribution of the Anticancer Drug Doxorubicin in Relation to Blood Vessels in Solid Tumors , 2005, Clinical Cancer Research.
[54] Mauro Ferrari,et al. Morphologic Instability and Cancer Invasion , 2005, Clinical Cancer Research.